Lumateperone

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 124 publications

Lumateperone (Caplyta) for adjunctive treatment of depression.

Lumateperone (Caplyta) for adjunctive treatment of depression.

Journal: The Medical letter on drugs and therapeutics

Published: January 23, 2026

Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Journal: The American journal of psychiatry

Published: December 01, 2025

Reply: Statistical limitations of the claimed dose-response in "Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials".

Reply: Statistical limitations of the claimed dose-response in "Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials".

Journal: Journal of psychopharmacology (Oxford, England)

Published: November 27, 2025

Statistical limitations of the claimed dose-response in "Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials".

Statistical limitations of the claimed dose-response in "Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials".

Journal: Journal of psychopharmacology (Oxford, England)

Published: November 27, 2025

Lumateperone Safety and Tolerability in Schizophrenia: A Narrative Review.

Lumateperone Safety and Tolerability in Schizophrenia: A Narrative Review.

Journal: Cureus

Published: November 04, 2025

Treatment of depressive episodes with mixed features: A systematic review and meta-analysis.

Treatment of depressive episodes with mixed features: A systematic review and meta-analysis.

Journal: General hospital psychiatry

Published: October 28, 2025

Efficacy of Lumateperone in Depression Associated With Bipolar II Disorder: A Pooled Analysis of Late-Phase Clinical Trials.

Efficacy of Lumateperone in Depression Associated With Bipolar II Disorder: A Pooled Analysis of Late-Phase Clinical Trials.

Journal: CNS spectrums

Published: September 29, 2025

Valbenazine for the Treatment of Chronic Motor or Vocal Tic Disorder (CMVTD).

Valbenazine for the Treatment of Chronic Motor or Vocal Tic Disorder (CMVTD).

Journal: Cureus

Published: September 19, 2025

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

Journal: The Journal of clinical psychiatry

Published: August 28, 2025

Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials.

Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials.

Journal: Journal of psychopharmacology (Oxford, England)

Published: August 28, 2025

Efficacy and Safety of Cariprazine, Asenapine, Xanomeline-Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis.

Efficacy and Safety of Cariprazine, Asenapine, Xanomeline-Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis.

Journal: Schizophrenia bulletin open

Published: August 21, 2025

Partial D2 receptors agonists - pharmacological aspects, metabolism and use in the treatment of schizophrenia-related psychoses

Partial D2 receptors agonists - pharmacological aspects, metabolism and use in the treatment of schizophrenia-related psychoses

Journal: Postepy biochemii

Published: August 17, 2025

Showing 1-12 of 124

Last Updated: 02/24/2026